ORAMED PHARMACEUTICALS INC. ORMP
engaged in the research and development of innovative pharmaceutical solutions with a technology platform that allows for the oral delivery
of therapeutic proteins. In addition, we allocate capital to strategic investments in healthcare and life sciences companies that we
believe complement our long-term business objectives and technology focus.
dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | — | $1.3M | $2.7M | $2.7M | $2.7M | $2.7M | $2.4M | $2.5M | $641.0K |
| Cost of revenue | $2.0M | — | — | — | — | — | $90.0K | -$86.0K | $187.0K | $490.0K |
| Gross profit | $13.0K | — | — | — | — | — | $2.6M | $2.5M | $2.3M | $151.0K |
| R&D | $6.4M | $6.3M | $9.0M | $27.6M | $21.0M | $10.2M | $13.5M | $12.0M | $10.3M | $7.7M |
| SG&A | $8.7M | $6.5M | $8.4M | $13.8M | $5.9M | $4.2M | $3.7M | $4.1M | $2.8M | $2.5M |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M | -$24.2M | -$11.8M | -$14.6M | -$13.5M | -$10.8M | -$10.0M |
| Interest expense | — | $853.0K | $2.0M | — | — | — | — | — | — | — |
| Pre-tax income | $75.3M | -$15.9M | $5.1M | -$37.7M | — | -$11.5M | -$14.1M | -$12.7M | -$10.1M | -$9.6M |
| Income tax | $11.3M | $3.2M | — | $100.0K | — | — | $300.0K | — | $400.0K | $1.3M |
| Net income | $75.3K | -$15.9K | $5.1K | -$36.6M | -$23.0M | -$11.5M | -$14.4M | -$12.7M | -$10.5M | -$11.0M |
| EPS, basic | 1.53 | -0.48 | 0.14 | -0.94 | — | — | — | — | — | — |
| EPS, diluted | 1.50 | -0.48 | 0.14 | -0.94 | 0.78 | 0.56 | 0.82 | 0.86 | 0.79 | 0.87 |
| Shares, diluted (wtd. avg.) | $42.4M | $40.9M | $40.6M | $39.0M | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.9M | $54.4M | $9.1M | $40.5M | $27.5M | $19.3M | $3.3M | $5.0M | $4.0M | $3.9M |
| Short-term investments | $5.4M | $3.4M | $57.7M | $3.7M | $863.0K | $3.3M | $557.0K | $666.0K | $996.0K | $701.0K |
| Total current assets | $133.3M | $143.2M | $162.6M | $157.1M | $147.9M | $40.5M | $33.3M | $31.0M | $20.3M | $31.2M |
| Property, plant and equipment | $586.0K | $698.0K | $873.0K | $815.0K | $388.0K | $99.0K | $24.0K | $17.0K | $18.0K | $16.0K |
| Total assets | $230.9M | $155.3M | $220.6M | $161.6M | $177.8M | $44.6M | $34.7M | $47.4M | $38.7M | $42.8M |
| Accounts payable | $443.0K | $789.0K | $551.0K | $4.2M | $4.5M | $1.7M | $2.5M | $2.1M | $2.7M | $1.4M |
| Short-term debt | — | — | $99.5M | — | — | — | $2.7M | $2.4M | — | — |
| Total current liabilities | $19.1M | $5.7M | $53.2M | $5.7M | $7.4M | $4.5M | $5.3M | $4.6M | $5.2M | $3.6M |
| Long-term debt | — | — | — | $25.0K | — | — | $9.7M | $11.4M | — | — |
| Retained earnings | -$123.4M | -$176.6M | -$157.6M | -$163.1M | -$126.5M | -$92.6M | -$81.1M | -$69.2M | -$56.5M | -$46.0M |
| Total equity | $199.7M | $146.3M | $162.9M | $151.2M | $166.6M | $32.9M | $19.4M | $31.1M | $19.2M | $26.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.1M | -$8.4M | -$10.3M | -$27.9M | -$21.2M | -$12.4M | -$12.9M | -$14.7M | -$5.8M | $4.7M |
| Depreciation and amortisation | $121.0K | $193.0K | $196.0K | $58.0K | $77.0K | $7.0K | $8.0K | $6.0K | $5.0K | $4.0K |
| Stock-based compensation | $6.0M | $4.1M | $4.2M | $11.5M | $2.7M | $465.0K | $808.0K | $1.5M | $1.6M | $634.0K |
| Capital expenditure | $9.0K | $18.0K | $254.0K | $496.0K | $375.0K | $82.0K | $15.0K | $5.0K | $7.0K | $9.0K |
| Investing cash flow | $5.4M | $105.8M | -$73.0M | $30.2M | -$23.8M | $4.6M | $11.3M | -$7.0M | $4.3M | -$16.0M |
| Financing cash flow | -$4.7M | -$52.0M | $52.0M | $10.8M | $102.9M | $23.8M | — | $22.7M | $1.6M | $12.0M |
| Buybacks | $4.7M | $2.5M | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-084609.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |